수술 전후 TNF Inhibitor의 사용 = TNF Inhibitor Use during the Perioperative Period

다국어 초록 (Multilingual Abstract)

Tumor necrosis factor (TNF) inhibitors are now established as therapeutic agents for treating active rheumatoid arthritis (RA) that is resistant to conventional drug treatment. However, TNF Inhibitors decrease resistance to infection, including unusual infections such as tuberculosis, and they have been shown to impair wound healing in an experimental setting. To date, there is limited data on patients with RA regarding their infections or the complications of surgery performed while taking TNF inhibitors and there is no professional consensus about this. This problem emphasizes a need for awareness and communication between patients, the rheumatologist and the surgeon when treating patients with RA. We reviewed the effects of TNF inhibitors on the incidence of surgical site infection (SSI) and the risk factors for SSIs after performing elective surgery in patients with RA. TNF inhibitors should not be used during the perioperative period until conclusive evidence to the contrary is available.

참고문헌 (Reference)

1 이연아, "수술 전후 관절염 환자의 약물 조절" 대한류마티스학회 15 (15): 101-109, 2008

2 Furst DE, "Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory disease" 62 (62): 2-9, 2003

3 Giles JT, "Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis" 55 : 333-337, 2006

4 Wolfe F, "The long-term outcomes of rheumatoid arthritis: a 23-year prospective longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis" 41 : 1072-1082, 198

5 Hultgren O, "TNF/Lymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus" 161 : 5937-5942, 1998

6 Wendling D, "Surgery in patients receiving anti-tumour necrosis factor α treatment in rheumatoid arthritis: an observational study on 50 surgical procedures" 64 : 1378-1379, 2005

7 Giles JT, "Serious infections associated with anti-cytokine therapies in the rheumatic diseases" 19 : 320-334, 2004

8 Den Broeder AA, "Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective stu" 34 : 689-695, 2007

9 Hamalainen M, "Postoperative wound infection in rheumatoid arthritis surgery" 3 : 329-335, 1984

10 Rosandich PA, "Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers" 16 : 192-198, 2004

11 Colombel JF, "Perioperative infliximab and/or immunomodulator therapy is not associated with increased postoperative complications in Crohn's disease" Digestive Diseases Week 2003

12 Verstappen SMM, "Occurrence and predictors of joint surgery in the Utrecht rheumatoid arthritis cohort" 64 : 216-, 2005

13 Olsen NJ, "New drugs for rheumatoid arthritis" 350 : 2167-2179, 2004

14 Grennan DM, "Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery" 60 : 214-217, 2001

15 Brzezinski A, "Infliximab dose not increase the risk of complications in the perioperative period in patients with Crohn's disease" Digestive Diseases Week 2002

16 Marchal L, "Infliximab dose not increase postoperative rates in patients with Crohn`s disease" Digestive Diseases Week 2003

17 Bibbo C, "Infection and healing complications after elective orthopedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy" 25 : 331-335, 2004

18 Bongartz T, "Incidence and risk factors for prosthetic joint infections in patients with rheumatoid arthritis following total knee and total hip replacement" 52 : 1449-, 2005

19 Phillips K, "Experience with etanercept in an academic medical center: are infection rates increased?" 47 : 17-21, 2002

20 Da Silva E, "Declining use of orthopadic surgery in patients with rheumatoid arthritis? Results of a longterm, population-based assessment" 49 : 216-220, 2003

21 Choy EH, "Cytokine pathways and joint inflammation in rheumatoid arthritis" 344 : 907-916, 2001

22 Ruyssen-Witrand A, "Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers" 25 : 430-436, 2007

23 "Club rhumatismes et inflammation: Fishes practiques: conduite a tenir chez les patients sous anti-TNF devant une chirurgie, avis d'experts"

24 Saag KG, "American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arhtirtis" 59 : 762-784, 2008